Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyResearch in context

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyResearch in context

Summary: Background: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. In this phase 2 study (CITADEL-205; NCT03235544, EudraCT 2017-003148-19), the efficacy and safety of parsaclisib was eval...

Full description

Bibliographic Details
Main Authors: Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, Vittorio Ruggero Zilioli, Jan Walewski, Jacob Haaber Christensen, Vincent Delwail, Guillermo Rodriguez, Parameswaran Venugopal, Morton Coleman, Caroline Dartigeas, Caterina Patti, Fabrizio Pane, Wojciech Jurczak, Michal Taszner, Shankara Paneesha, Fred Zheng, Douglas J. DeMarini, Wei Jiang, Aidan Gilmartin, Amitkumar Mehta
Format: Article
Language:English
Published: Elsevier 2023-08-01
Series:EClinicalMedicine
Subjects:
Mantle cell lymphoma
B-cell lymphoma
Non-Hodgkin lymphoma
PI3K inhibitor
Parsaclisib
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537023003085

Internet

http://www.sciencedirect.com/science/article/pii/S2589537023003085

Similar Items